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Abstract
IMPORTANCE Little is known about the association between the coronavirus disease 2019
(COVID-19) pandemic and the level and content of primary care delivery in the US.
OBJECTIVE To quantify national changes in the volume, type, and content of primary care delivered
during the COVID-19 pandemic, especially with regard to office-based vs telemedicine encounters.
DESIGN, SETTING, AND PARTICIPANTS Analysis of serial cross-sectional data from the IQVIA
National Disease and Therapeutic Index, a 2-stage, stratified nationally representative audit of
outpatient care in the US from the first calendar quarter (Q1) of 2018 to the second calendar quarter
(Q2) of 2020.
MAIN OUTCOMES AND MEASURES Visit type (office-based or telemedicine), overall and stratified
by patient population and geographic region; assessment of blood pressure or cholesterol
measurement; and initiation or continuation of prescription medications.
RESULTS In the 8 calendar quarters between January 1, 2018, and December 31, 2019, between
122.4 million (95% CI, 117.3-127.5 million) and 130.3 million (95% CI, 124.7-135.9 million) quarterly
primary care visits occurred in the US (mean, 125.8 million; 95% CI, 121.7-129.9 million), most of which
were office-based (92.9%). In 2020, the total number of encounters decreased to 117.9 million (95%
CI, 112.6-123.2 million) in Q1 and 99.3 million (95% CI, 94.9-103.8 million) in Q2, a decrease of 21.4%
(27.0 million visits) from the average of Q2 levels during 2018 and 2019. Office-based visits
decreased 50.2% (59.1 million visits) in Q2 of 2020 compared with Q2 2018-2019, while telemedicine
visits increased from 1.1% of total Q2 2018-2019 visits (1.4 million quarterly visits) to 4.1% in Q1 of
2020 (4.8 million visits) and 35.3% in Q2 of 2020 (35.0 million visits). Decreases occurred in blood
pressure level assessment (50.1% decrease, 44.4 million visits) and cholesterol level assessment
(36.9% decrease, 10.2 million visits) in Q2 of 2020 compared with Q2 2018-2019 levels, and
assessment was less common during telemedicine than during office-based visits (9.6% vs 69.7% for
blood pressure; P < .001; 13.5% vs 21.6% for cholesterol; P < .001). New medication visits in Q2 of
2020 decreased by 26.0% (14.1 million visits) from Q2 2018-2019 levels. Telemedicine adoption
occurred at similar rates among White individuals and Black individuals (19.3% vs 20.5% of patient
visits, respectively, in Q1/Q2 of 2020), varied by region (low of 15.1% of visits [East North Central
region], high of 26.8% of visits [Pacific region]), and was not correlated with regional COVID-
19 burden.
CONCLUSIONS AND RELEVANCE The COVID-19 pandemic has been associated with changes in the
structure of primary care delivery, with the content of telemedicine visits differing from that of
office-based encounters.
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Key Points
Question Is there a quantifiable
association between the coronavirus
disease 2019 (COVID-19) pandemic and
the volume, type, and content of
primary care encounters in the US?
Findings In this cross-sectional analysis
of the US National Disease and
Therapeutic Index audit of more than
125.8 million primary care visits in the 10
calendar quarters between quarter 1 of
2018 and quarter 2 of 2020, primary
care visits decreased by 21.4% during
the second quarter of 2020 compared
with the average quarterly visit volume
of the second quarters of 2018 and
2019. Evaluations of blood pressure and
cholesterol levels decreased owing to
fewer total visits and less frequent
assessment during telemedicine
encounters.
Meaning The COVID-19 pandemic was
associated with changes in the structure
of primary care delivery during the
second quarter of 2020, with the
content of telemedicine visits differing
from that of office-based encounters.
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Introduction
Since February 2020, the coronavirus disease 2019 (COVID-19) pandemic has been associated with
more than 4.4 million cases and 150 000 deaths in the US, as well as widespread social and economic
changes.1 While the ultimate health care system impacts of the pandemic remain uncertain, many
early health care consequences associated with the pandemic have been noted, ranging from
postponement of elective care to permanent clinic and hospital closures.2,3
Early reports suggested that substantial increases could be expected in the delivery of
telemedicine, or remote clinical services, during the first few months of the pandemic in the US,4,5
owing to concern regarding the potential for workplace transmission of COVID-19, the
implementation of social distancing policies, and the redeployment of health care personnel. A more
recent update indicated that the delivery of telemedicine increased during mid-April and has since
subsided modestly, although levels remain substantially higher than before the pandemic.6 These
changes, which have been accompanied by changes in federal7,8 and state9,10 guidance and
reimbursement, have occurred in the context of structural and social factors11,12 hindering
widespread telemedicine adoption.
Investigations of telemedicine during the pandemic, while yielding insights, have generally been
based on small or nonrepresentative samples and limited to analyses of the frequency of such
encounters rather than descriptions of their content.4-6,13 We quantified national changes in the
volume and type of primary care associated with the COVID-19 pandemic. In addition to
characterizing blood pressure and cholesterol measurement and initiation or continuation of
prescription medicines for hypertension and dyslipidemia, we explored variance in telemedicine use
across different patient populations and geographic regions of the US.
Methods
Data
We used the IQVIA National Disease and Therapeutic Index to conduct a cross-sectional analysis,
focusing on the period from the first quarter (Q1) of 2018 through the second quarter (Q2) of 2020.
The National Disease and Therapeutic Index is a nationally representative audit of outpatient practice
in the US.14,15 Other studies16-18 have compared the National Disease and Therapeutic Index with the
National Ambulatory Medical Care Survey, a nationally representative audit conducted by the
National Center for Health Statistics, and found that the surveys yielded substantively comparable
estimates of outpatient care. Using a 2-stage, stratified sampling design, the National Disease and
Therapeutic Index audit is based on a sample derived from the American Medical Association and the
American Osteopathic Association.19 Data are collected from approximately 4000 physicians during
each calendar quarter, during which participants complete a form for 2 consecutive days
documenting each patient encounter, including demographic information, diagnoses, and treatment
provided. Diagnostic information is reported using a system similar to the International Classification
of Diseases, Ninth Revision. The original development of the National Disease and Therapeutic Index
was limited to the contiguous US because of statistical sampling and design considerations; as a
result, physician reporting from Alaska and Hawaii are excluded. Each encounter is also classified
based on site of care, including office-based, hospital-based, telemedicine, or other (such as home,
nursing facility, or other institutional setting). Clinician-reported demographic information about
individuals, such as patient age, sex, and race, were also assessed. Data were then weighted to
provide nationally representative estimates as well as estimates that are representative across 8
geographic regions (Pacific, East South Central, West South Central, West North Central, Mountain,
South Atlantic, East North Central, and New England and Mid-Atlantic) (eTable 1 in the Supplement).
This study was deemed exempt from institutional review board review by the Johns Hopkins
Bloomberg School of Public Health per regulations found at 45 CFR 46. This study followed the
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Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline
for cross-sectional studies.20
We restricted our analysis to primary care visits, defined as those accounted for by the fields of
internal medicine, pediatrics, geriatrics, general practice, and family practice. For cases in which we
specifically assessed pharmaceutical prescribing (eg, initiations of pharmacologic therapy for specific
diseases), we examined treatment visit, defined as a patient encounter for a specific diagnosis in
which a pharmacologic treatment was initiated or continued. Except where depicted otherwise, we
excluded the approximately 3% to 4% of hospital-based visits and 1% to 2% of visits taking place in
other settings (home, nursing home, and unspecified sites of care) each calendar quarter.
Our analysis of telemedicine use across geographic regions included an examination of how
such use varied by COVID-19 burden, expressed as the rate of COVID-19 fatalities per 100 000
individuals. To estimate this rate, we summed COVID-19 deaths within each national region as of July
28, 2020,21 and divided this number by the total population within that region.22
Statistical Analysis
We used descriptive statistics to perform our analysis. Our main outcomes were visit type,
assessment of blood pressure or cholesterol measurement, and initiation or continuation of
prescription medicines. First, we extracted the total number of visits between January 1, 2018, and
June 30, 2020, and plotted these numbers over time to examine general trends and to assess for
inflection points and outliers. Next, we aggregated these visits by calendar quarter. We then
characterized the distribution of visits, stratified by encounter type, across visit characteristics of
interest, such as patient age, sex, race, and type of insurance. We limited our analysis of telemedicine
use by race to Black race and White race given racial disparities in health care. We calculated a
Pearson correlation coefficient to examine the association between telemedicine use and COVID-19
burden across 8 geographic regions. We used standardized errors to estimate 95% CIs. Analyses
used 2-tailed, unpaired testing. A threshold of P < .05 was used to establish statistical significance.
Statistical analyses were conducted using Stata software, version 15 (StataCorp LLC).
Results
Trends in Primary Care Visits by Encounter Type
In the 8 calendar quarters between January 1, 2018, and December 31, 2019, between 122.4 million
(95% CI, 117.3-127.5 million) and 130.3 million (95% CI, 124.7-135.9 million) quarterly primary care
visits occurred in the US (mean, 125.8 million; 95% CI, 121.7-129.9 million) (Table 1) (eFigure in the
Supplement). In 2020, the total number of encounters decreased to 117.9 million (95% CI, 112.6-123.2
million) in Q1 and 99.3 million (95% CI, 94.9-103.8 million) in Q2, a decrease of 21.4% (27.0 million
visits) from the average number of Q2 encounters in 2018 and 2019.
Most primary care encounters in 2018-2019 were office-based (92.9%). Office-based visits
decreased from a mean of 116.9 million (95% CI, 111.6-122.1 million) for the average quarterly visit
volume in 2018-2019 to 105.9 million (95% CI, 101.2-110.7 million) in Q1 of 2020, then 58.7 million
(95% CI, 55.3-62.1 million) in Q2 of 2020, a decrease of 50.2% (59.1 million visits) compared with Q2
2018-2019 levels. By contrast, telemedicine visits increased from 1.1% of visits in 2018-2019 to 4.1%
in Q1 of 2020 and 35.3% of visits in Q2 of 2020.
Primary Care Visits by Race and Other Patient Characteristics
Table 2 presents the use of office-based and telemedicine visits stratified by patient race. For
example, during the first 2 quarters of 2018, there were 158.8 million (95% CI, 152.1-165.4 million)
patient visits among White individuals (85.6% of visits among White or Black individuals) and 26.7
million (95% CI, 24.6-28.7 million) patient visits among Black individuals (14.4%). Visits for Black
individuals accounted for between 14.4% and 17.4% of visits of the period examined, and increases
in telemedicine visits were similar among White individuals and Black individuals, with telemedicine
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visits accounting for 19.3% of 2020 treatment visits among White individuals and 20.5% of those of
Black individuals.
eTable 2 in the Supplement presents the distribution of office-based and telemedicine visits
stratified by patient age, sex, and insurance type (commercial, Medicaid, or other). Whereas
individuals aged 19 to 35 years and aged 36 to 55 years accounted for 12.4% and 19.8% of office-
based visits, respectively, in Q1/Q2 of 2020, they accounted for 17.8% and 26.1% of telemedicine
visits, respectively, during this period, indicating substantial adoption of telemedicine compared with
their younger or older counterparts (15.6% of telemedicine visits were individuals aged <19 years and
15.2% and 25.3% of visits were individuals aged 56-65 years and 66 years, respectively).
Commercially insured visits accounted for an average of 60.3% of office-based visits for Q1 and Q2
of 2020 and an average of 57.3% of telemedicine visits for Q1 and Q2 of 2020.
Geographic Variation in Telemedicine Use
Table 3 and the Figure depict 2020 primary care office-based and telemedicine visits in the US
stratified by geographic region. For example, during the first 2 quarters of 2020, there were 39.6
million (95% CI, 36.8-42.4 million) visits in the Pacific region (Washington, Oregon, and California).
Of these visits, 10.6 million (95% CI, 9.2-12.1 million) (26.8%) were telemedicine encounters. The
proportion of visits delivered by telemedicine varied from a low of 15.1% in the East North Central
region (Wisconsin, Michigan, Illinois, Indiana, and Ohio) to a high of 26.8% in the Pacific region.
Table 3 also presents the burden of the pandemic across these regions, with a case fatality rate that
ranged from 19.90 to 124.91 per 100 000 individuals. There was no association between the use of
telemedicine and the pandemic burden across geographic regions (r = 0.004; P = .99).
Features of Primary Care Office-Based and Telemedicine Visits
Table 4 and eTable 3 in the Supplement characterize the content of primary care visits over time,
showing reductions in care assessment. For example, blood pressure was assessed in an estimated
88.7 million (95% CI, 84.6-92.7 million) Q2 visits in 2018/2019, 75.9 million (95% CI, 72.0-79.7
million) visits in Q1 of 2020, and 44.2 million (95% CI, 41.1-47.4 million) visits in Q2 of 2020, reflecting
a 50.1% decrease (44.4 million visits) from Q2 2018-2019 levels. The absolute number of cholesterol
assessments decreased 36.9% over the same period (10.2 million visits), while reductions in the
absolute number of office-based and telemedicine visits with the initiation (26.0%) or continuation
(8.9%) of new medicines were also noted.
One reason for this finding was that assessment of blood pressure and cholesterol was
statistically significantly less common among telemedicine than among office-based visits. For
example, of 58.7 million (95% CI, 55.3-62.1 million) Q2 2020 office-based visits, 69.7% had a blood
pressure recorded compared with 9.6% of telemedicine visits during the same time period
Table 3. Primary Care Office-Based and Telemedicine Visits by Geographic Region and COVID-19 Burden,
First 2 Quarters of 2020a
Geographic region
COVID-19 death
rate (per 100 000
individuals)
Visits, No. in thousands (95% CI)
Telemedicine
% of totalOffice-based Telemedicine
Pacific 19.90 29 000 (26 637-31 364) 10 631 (9158-12 104) 26.8
East South Central 24.23 9033 (7718-10 348) 1928 (1386-2470) 17.6
West South Central 25.30 14 792 (12 742-16 842) 2908 (2215-3601) 16.4
West North Central 21.11 8807 (7525-10 089) 1711 (1230-2192) 16.3
Mountain 27.62 9959 (8579-11 339) 2394 (1722-3066) 19.4
South Atlantic 29.65 36 238 (33 676-38 800) 8146 (6892-9400) 18.4
East North Central 44.97 27 402 (25 169-29 635) 4856 (3929-5783) 15.1
New England and
Mid-Atlantic
124.91 29 349 (26 957-31 741) 7263 (6074-8452) 19.8
All regions 45.24 164 579 (157 189-171 969) 39 838 (37 021-42 655) 19.5
Abbreviation: COVID-19, coronavirus disease 2019.
a Source: IQVIA National Disease and Therapeutic
Index, 2018-2020.19
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(P < .001). Cholesterol was also less commonly assessed during telemedicine than during office-
based visits (13.5% vs 21.6% of Q2 2020 visits; P < .001). New prescription medications were
ordered similar proportions of Q2 2020 telemedicine and office-based visits (39.3% vs 44.9%), but
absolute numbers across these visit types decreased from 54.1 million (95% CI, 50.8-57.5 million) in
Q2 2018/2019 to 51.8 million (95% CI, 48.5-55.1 million) in Q1 of 2020 and 40.1 million (95% CI,
37.2-42.9 million) in Q2 of 2020, representing a 26.0% decrease from Q2 2018-2019 volume.
Discussion
While the COVID-19 pandemic has impacted health care delivery in many ways, little is known
regarding how the volume, site, and content of primary care in the US has changed. We used a
nationally representative audit of outpatient care to characterize primary care delivery in the US
Figure. Geographic Variation in COVID-19 Burden and Telemedicine Adoption in the First 2 Quarters of 2020
Lowest tertile (19.9-25.3)









COVID-19 death rateA Telemedicine adoptionB
COVID-19 indicates coronavirus disease 2019.
Table 4. Content of Primary Care Office-Based and Telemedicine Visits, 2018-2020a
Variable
No., in thousands (%)
% Change (2020 Q2








(89 270-98 154) −21.4
Blood pressure
recorded 88 675 (74.4)
75 852 (68.5) 44 229 (47.2) −50.1
Cholesterol assessed 27 617 (23.2) 22 803 (20.6) 17 413 (18.5) −36.9
New medicines
initiated 54 142 (45.4)
51 773 (46.8) 40 079 (42.8) −26.0
Medicines continued 38 024 (31.9) 35 541 (32.1) 34 621 (36.9) −8.9
New treatment visits
Hypertension 3414 (2.9) 2714 (2.5) 2078 (2.2) −39.1
Diabetes 1408 (1.2) 1226 (1.1) 1177 (1.3) −16.4
High cholesterol 1274 (1.1) 1326 (1.2) 926 (1.0) −27.3
Asthma 1266 (1.1) 1146 (1.0) 635 (0.7) −49.8
Depression 193 (0.2) 157 (0.1) 149 (0.2) −22.8
Insomnia 396 (0.3) 437 (0.4) 299 (0.3) −24.5
Abbreviation: Q, quarter.
a Values represent average second quarter visit
volume (2018-2019) and quarterly visit volume
(2020 Q1 and 2020 Q2).
b Percentage change depicts a comparison of the
second quarter of 2020 (2020 Q2) with average
volume of 2018 Q2 and 2019 Q2 combined.
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between 2018 and Q2 of 2020. The pandemic has been associated with a more than 25% decrease
in primary care volume, which has been offset in part by increases in the delivery of telemedicine,
which accounted for 35.28% of encounters during the second quarter of 2020. Despite the
increased use of telemedicine, its uptake has varied across the continental US and has not been
correlated, at a regional level, with COVID-19 burden. Overall, the pandemic has been associated with
marked reductions in the primary care assessment of cardiovascular risk factors such as blood
pressure and cholesterol levels, owing to decreased total visit volume and less frequent assessment
during telemedicine visits than during office-based visits. These findings are notable because little is
known about the association between primary care delivery and the COVID-19 pandemic and
because the pandemic has generated interest in telemedicine as a means to safely deliver
primary care.
Our analysis was based on an assessment at a single point, and the degree to which the
COVID-19 pandemic may be associated with permanent increases in the use of telemedicine remains
to be seen. Historically, limited reimbursement, interstate licensure requirements, and patient and
clinician factors have slowed the uptake and adoption of telemedicine.12,23 In response to the
pandemic, US federal and state agencies and other stakeholders have modified policies and
procedures, such as the Centers for Medicare & Medicaid Services provision of telehealth waivers for
providers,24 to allow greater use of telemedicine to support remote clinical encounters.25,26 We did
not find a correlation between regional COVID-19 burden and telemedicine adoption, suggesting that
other factors may account for regional differences in the uptake of this mode of health care. In
addition, whether the federal and state rules and regulations that have been modified will be made
permanent and whether the current embrace of telemedicine by patients and clinicians will endure
remain unknown.27
If substantial primary care volume continues to be delivered using telemedicine, a focus on the
content and quality of such encounters is inevitable.28 Despite findings in a systematic review of 86
articles demonstrating the feasibility and acceptance of telemedicine for use in primary care, to our
knowledge, relatively few rigorous comparisons of clinical outcomes in office-based vs telemedicine
encounters have been performed.29 Our finding that such visits were less likely to include blood
pressure or cholesterol assessments underscores the limitation of telemedicine, at least in its current
form, for an important component of primary care prevention and chronic disease management.
Middle-aged individuals and those who were commercially insured were more likely to adopt
telemedicine during the pandemic than their counterparts with other or no insurance. This difference
may be due in part to the perceived elective or deferrable nature of visits among children30 and
greater familiarity with telemedicine technology among middle-aged than among older adults.31 We
did not find substantial differences in telemedicine use by payer type, and, contrary to our
expectations and evidence of a digital divide,32 we did not find evidence of a racial disparity in
telemedicine use when examining the frequency of telemedicine encounters as a proportion of a
patient visits among Black versus White individuals.
Limitations
This study has limitations. First, both the COVID-19 pandemic and health system response continue
to evolve, and our analyses reflect the provision of care at a single point in time. Second, as with any
outpatient audit, the data that we used were subject to measurement error, although prior analyses
have yielded estimates comparable to those from the National Ambulatory Medical Care Survey.
Third, factors such as patient race are complex multidimensional constructs, and our assessment of
race in this context provides a limited window through which to understand how telemedicine
adoption may vary across different populations.33,34 Fourth, our data did not allow us to examine
more granular geographic associations between COVID-19 burden and telemedicine adoption. Last,
we considered the assessment of 2 important cardiovascular risk factors, but many other dimensions
of primary care might also be compared between office-based and telemedicine encounters, and we
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did not attempt to assess the association between primary care encounter type and overall quality
of care.
Conclusions
More than 4 months after the US Department of Health and Human Services declared a public health
emergency, widespread economic and social changes in the US during the COVID-19 pandemic are
still occurring. The pandemic has been associated with substantial decreases in primary care delivery,
despite large increases in the use of telemedicine, which accounted for fewer than 2% of primary
care visits during 2019 yet more than 35% of visits during Q2 of 2020. Evaluations of cardiovascular
risk factors such as blood pressure and cholesterol have decreased, owing to fewer total visits and
less frequent assessment during telemedicine encounters. Thus, the COVID-19 pandemic has been
associated with changes in the structure of primary care, with the content of telemedicine visits
differing from that of office-based encounters.
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